anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a cosmetic agent for hair which possesses unsticky, unfettered usability, affords soft touch and gives no greasiness and creak to hair by formulating a specific natural plant component thereto. SOLUTION: This material is prepared by formulating unsaturated aliphatic alcohols which consist of carbon atoms of 14-24 containing one double bond. As the unsaturated aliphatic alcohols, e.g. jojoba alcohol, 2- tetradecenol-1(cis)(C14 ), 2-pentadeccenol-1(cis)(C15 ) and 2-heptadecenol-1(cis)(C17 ) are illustrated. Particularly preferable sybstabce is jojoba alcohol. The unsaturated aliphatic alcohols are formulated in an amount of 0.1-50.5wt.%, preferably about 1.0-25.0wt.%, based on the whole amount of the cosmetic material for hair. The cosmetic material for hair is usable as e.g. aerosol type spray, pump style hair spray, foam aerosol, set-lotion and hair oil.
The present invention relates to methods for altering the retention time of RNA on a chromatography column. The invention also relates to a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the invention provides methods for coordinating the number of a and/or U nucleotides in at least two RNA species. The invention also relates to RNAs obtainable by said method, compositions comprising said RNAs, or vaccines comprising said RNAs, and methods of making such RNAs and compositions. Furthermore, the present invention relates to a kit, in particular a kit of parts, comprising an RNA, a composition or a vaccine. The invention also relates to methods of treating or preventing a disorder or disease, first and second pharmaceutical uses of the RNA, compositions, and vaccines. Furthermore, the present invention relates to methods of providing a modified RNA sequence or a modified RNA mixture.
Participants will not receive calibration of electromyography. Measurements will start simultaneously to the standard electromyography with a default current of 60mA at state entropy of 50.
RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single intravenous (IV) infusion. Subjects will receive one of three dose levels depending on the cohort.
For the past two decades, Bangladesh has faced recurrent dengue outbreaks, with the most recent occurring in 2023. We investigated the socioeconomic, clinical, and laboratory aspects of patients diagnosed with dengue during this outbreak. This observational study was conducted from July to September 2023 at Dhaka Medical College Hospital and Chittagong Medical College Hospital, and included 450 confirmed cases of dengue. Sociodemographic information was collected via face-to-face interviews, clinical examinations, and laboratory testing, which was done within 24 hours of admission. Dengue severity was classified according to the 2009 WHO dengue guidelines. Notably, 17% of patients experienced severe dengue, and 89% of those with nonsevere cases exhibited at least one warning sign. Most patients were young adults (mean age, 33 years), with a nearly equal male-to-female ratio. Common clinical presentations included fever (95%), myalgia (62%), and headache (58%), whereas warning signs such as vomiting (54%) and abdominal pain (39%) were prevalent. Plasma leakage indicators, including ascites, pleural effusion, and edema, were found predominantly in severe cases. Laboratory findings revealed leukopenia, thrombocytopenia, and elevated hepatic enzymes (alanine aminotransferase and aspartate aminotransferase) in nearly half the patients. An elevated hematocrit level was associated with severe dengue. We report that a substantial number of patients developed severe dengue during the epidemic in 2023, and provide detailed clinical-epidemiological profiles of the patients, offering valuable insight into management of dengue cases.
Elements (5) such as dental fillings, inlays, dental veneers, root pins, implants to be implanted in bone tissue, or endoprostheses are affixed to surfaces (3) of dentine, tooth enamel, bone tissue, or a corresponding substitute material, by providing the element with element surfaces (6) comprising a first thermoplastic material, by equipping the surfaces (3) of dentine, tooth enamel, bone tissue, or a corresponding substitute material in a preparatory step in such a way that they become weldable with the first thermoplastic material, and by welding the element surfaces (6) to the pretreated surfaces (3) by e.g. exciting the appropriately positioned element (5) with mechanical vibrations. The pre-treatment of the surfaces (3) in the preparatory step is achieved by attaching solid bodies (2) comprising a second thermoplastic material to said surfaces (3), with the aid of a curable compound (generally known for preparatory treatment of dentine or enamel surfaces) or with the aid of a cement. Therein the first and second thermoplastic materials are selected to be capable of being welded together. The solid bodies (2) are particles, fibers, or they are combined in a flat item. The resulting fixation is based on a fusion of the element surfaces (6) and the solid bodies (2).
Minocycline has excellent penetration of the blood-brain barrier. In a mechanism that seems to be distinct from its antimicrobial properties, minocycline has anti-inflammatory and neuroprotective properties. These properties are thought to be related to some combination of its inhibition of inducible nitric oxide synthase (iNOS); caspase 1 and 3; p-38 mitogen-activated protein kinase (MAPK); cytochrome C release; cyclooxygenase-2 expression; prostaglandin E2 formation; and microglial activation. Minocycline has also been reported to have antiviral effects against HIV and antiprotozoal effects against Toxoplasma gondii.

Its use in individuals with schizophrenia has been encouraged by its effects in rodent models of this disorder. In one study, minocycline attenuated the behavioral changes following the administration of an NMDA (N-methyl-D-aspartate)antagonist in mice. In another study, minocycline reversed the effects of an NMDA antagonist in rats. Some preliminary data also suggest that minocycline may be useful in patients with schizophrenia. Two case report series have been published, one including two patients with schizophrenia and the other including three patients with recent-onset acute paranoid schizophrenia. An open label study of 22 patients with treatment-resistant schizophrenia, using minocycline 150 mg/d for four weeks, reported an improvement in both positive and negative symptoms. Two double blind trials have been carried out. In one study, 73 patients with schizophrenia of less than five years' duration were randomized to minocycline 200 mg or placebo for 12 months: "all symptom measures improved significantly" especially in the negative symptoms. In the other study, 54 "early phase" (symptoms of less than five years) patients were randomized to minocycline 200 mg/d or placebo for six months; the authors reported a significant improvement in negative symptoms measured using Scale for the Assessment of Negative Symptoms (SANS) and Clinical Global Impressions scale (CGI) and a significant improvement in some test of executive function.

These initial findings encourage further replication. First, these studies are of comparatively small size. Second, in countries like Ethiopia where options for the treatment of schizophrenia are limited, identifying a safe alternative to clozapine is important. Related to this, most patients have limited exposure to psychotropic medications. Third, exposure to alcohol and substances is generally believed to be lower in the Ethiopian setting. Finally, given our hypothesis that infectious agents as a cause of schizophrenia may be more important in low and middle income countries (LAMICs) such as Ethiopia, minocycline may prove more useful. In this regard, the trial will help to explore the etiology of schizophrenia. The investigators have experience in following-up a large cohort of patients with schizophrenia and in conducting randomized controlled trials of a similar nature, which makes this proposed study feasible.
Oxaliplatin Injection USP is supplied in clear, glass, single-dose vials with gray elastomeric stoppers and aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin as a clear, colorless, sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL. 

NDC 68001-468-36: 50 mg/10 mL single-dose vial with flip-off seal individually packaged in a carton.

NDC 68001-468-37: 100 mg/20 mL single-dose vial with flip-off seal individually packaged in a carton.

Store at 25°C (77°F); excursions permitted between 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature]. Do not freeze and protect from light (keep in original outer carton). Discard unused portion.

Oxaliplatin Injection USP is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 The use of gloves is recommended. If a solution of Oxaliplatin Injection USP contacts the skin, wash the skin immediately and thoroughly with soap and water. If Oxaliplatin Injection USP contacts the mucous membranes, flush thoroughly with water.
PURPOSE: To provide a skin washing article, good in use feeling, having high detergency against oil staining and especially suitable for removing a makeup such as lipstick, eyeshadow, water resistant foundation, etc. CONSTITUTION: This skin washing article is prepared by filling a detergent composition in a foam discharging container having a porous film. The detergent composition contains 1-50wt.%, preferably 3-20wt.% of (A) an anionic surfactant, e.g. lauric acid triethanolamine, potassium salt of palm oil fatty acid and 0.5-30wt.%, especially 1-20wt.% of (B) a nonionic surfactant added with 1-50 mole, preferably 3-15 mole polyoxyalkylene group in average based on one hydrophobic group, e.g. polyoxyalkylene ethers or polyoxyethylene fatty acid esters. When 3-30wt.% polyol is added to the deterger composition, feeling becomes better in case of massaging with foams and moist feeling of the skin is good after washing out the detergent composition. When 0.1-10wt.% ethanol is added, tiny and creamy foams are obtained and the detergency of the detergent composition is enhanced.
<P>PROBLEM TO BE SOLVED: To provide a renal disease improving agent in dialysis patients, an agent for preventing and/or improving arteriosclerosis in dialysis patients or a functional food, and furthermore an application method using them.  <P>SOLUTION: The renal disease improving agent in dialysis patients and the agent for preventing and/or improving arteriosclerosis in dialysis patients contain coenzyme Q10 as an active ingredient. The functional food having a renal disease improving effect in dialysis patients and a preventing and/or improving effect on arteriosclerosis in dialysis patients contains the compound as an active ingredient. Coenzyme Q10 is used in preparing a composition for improving the renal disease in dialysis patients and for preventing and/or improving the arteriosclerosis in dialysis patients. A method of improving the renal disease in dialysis patients and a method of preventing and/or improving the arteriosclerosis in dialysis patients comprise taking in a composition containing the compound as an active ingredient.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Necrotizing enterocolitis (NEC) is a form of potentially lethal gastrointestinal inflammation that primarily affects preterm neonates. It is crucial to recognize that, while the disease carries significant risks, timely and effective medical intervention can greatly enhance the chances of survival. Additionally, NEC is closely linked to the activation of macrophages, highlighting the complex interplay between the immune response and disease progression. CD38, acting as an ectoenzyme, catalyzes the hydrolysis of NAD+ to produce cyclic ADP-ribose (cADPR), a reaction critical for modulating cellular redox balance and energy homeostasis. This enzymatic activity is particularly pertinent in the context of necrotizing enterocolitis (NEC). In this research, we investigated whether CD38 deletion can elevate NAD+ levels to reduce macrophage-mediated inflammation and improve NEC severity. We show that NEC patients was associated with the increased CD38 expression in intestine and blood. These results were also observed in NEC mice, and CD38 deletion ameliorated NEC intestinal injury. Mechanistically, CD38 deletion elevated NAD+ levels that reduced oxidative stress and intestinal inflammation. Furthermore, CD38 deletion promoted M2 macrophage polarization, inhibited macrophage activation and phagocytosis ability. Thus, our results reveal a critical role for CD38 as an intracellular immune regulator for regulating macrophage activation and intestinal inflammation in NEC. Targeting CD38 and NAD+ signal maybe a promising strategy for treatment of NEC.
Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.
Epigenetics, specifically histone post-translational modification (HPTM) induced by environmental factors, plays a crucial role in the development of diabetes. Sodium benzoate (NAB) is a widely used additive, however, its potential contribution to diabetes has been largely overlooked. In 2018, a novel HPTM called benzoylation (Kbz) induced by NAB was discovered. This modification can be catalyzed by ACSS2 (acyl-CoA synthetase short-chain member 2) and acyltransferase P300/CBP, and can be reversed by erase enzymes SIRT2. Studies have indicated that Kbz may regulate insulin secretion, although the exact molecular mechanism remains unclear. In our study, C57BL/6J mice were divided into two groups: the NC group and the 1g/kg NAB water feeding group. In vivo experiments were conducted using β-TC-6 cells, with 6 mM NAB or 100 μM benzoyl-CoA as stimuli, and 10 μM A485 (P300 inhibitor), 5 μM ACSS2 inhibitor (inhibiting benzoyl-CoA synthesis), or 5 μM AGK2 (SIRT2 inhibitor) as intervention factors. Our study found that, although the experimental concentration of NAB is below the maximum allowable concentration in food, it still damaged the insulin secretion function of C57BL/6J mice and induced inflammation and apoptosis of islet β cells. We observed significant differences in serum benzoyl-CoA levels between healthy individuals and patients with type 2 diabetes. Furthermore, NAB concentration-dependently increases benzoyl-CoA and Kbz levels. When Kbz is down-regulated using A485 and ACSS2 inhibitor, we observed a reduction in β cell inflammation, apoptosis, and insulin secretion damage. Conversely, up-regulating Kbz using AGK2 resulted in increased levels of β cell inflammation and apoptosis. In conclusion, our data suggest that NAB, despite being within the safe dose range, may be an overlooked environmental risk factor contributing to the pathogenesis of diabetes through its impact on Kbz.
Isolated cells that are not embryonic stem cells, not embryonic germ cells, and not germ cells are described. These cells are capable of differentiating into at least one cell type of each of at least two of the endodermal, ectodermal and mesodermal embryonic lineages. These cells do not elicit a deleterious immune response. These cells are capable of modulating immune responses. For example, these cells can suppress immune responses in the host caused by allogeneic cells, tissues and organs. Methods of using these cells, by themselves or adjunctively, to treat a subject are described. For example, these cells can be used adjunctively for immunosuppression in transplantation therapy. Methods of obtaining these cells and compositions using them are also described.
This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.
<P>PROBLEM TO BE SOLVED: To provide a new polymer-platinum compound having anti-tumor activity in vivo.  <P>SOLUTION: A polymer-platinum compound for use in tumor treatment is described. The compound is composed of a polymer backbone having platinum-containing side chains disposed at intervals along the polymer backbone. These side chains are composed of an oligopeptide attached at one end to the backbone and at the other end to the platinum compound. In one aspect, the invention includes a composition for use in a tumor treatment, which contains a polymer-platinum complex compound designed so as to accumulate at the tumor site.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE: A non-woven fabric containing coated or impregnated composition for preventing skin rash is provided to remove ammonia odor and to prevent skin rash. CONSTITUTION: A non-woven fabric for preventing skin rash contains a composition containing 35-48 wt% of ginkgo extract, 38-63 wt% of Acorus calamus var. extract, and 2-14 wt% of lacquer extract. The non-woven fabric has an antibacterial effect or ammonia deodorization effect. The composition additionally contains (-)epigallocatechin-3-gallate and Houttuynia cordata extract. (-)epigallocatechin-3-gallate is isolated from green tea extract. The Houttuynia cordata extract is prepared using water, anhydrous or hydrous low carbon number alcohol(methanol, ethanol, propanol, butanol), a mixture solvent of the low carbon number alcohol and water, acetone, ethyl acetate, chloroform or 1,3-butylene glycol.
This study is a Phase I, open label, non-randomized, dose-frequency escalation pharmacokinetics study among 24 healthy male and female subjects, aged 18 to 45 years to determine the pharmacokinetics and safety of high multi-dose cefixime for the treatment of reduced susceptibility gonorrhea. The study will occur in two stages as described below. Stage 1: Confirm/establish the pharmacokinetics (PK) of 400mg and 800mg doses of cefixime tablet. Stage 2: Define dosing frequency necessary to achieve total serum cefixime levels that exceed 2.0 mcg/mL for over 20 hours. Stage 1 (Cohorts A and B): Six subjects will be admitted to the Johns Hopkins Bayview Clinic Trials Unit to assess each dosing regimen, for a total of 12 subjects. At time=0, subjects will undergo baseline serum cefixime levels, followed by ingestion of cefixime. Serum collections will occur at times 0, 1, 2, 4, 8, 12, 16, 20, and 24 hours. Cohort B will have the same serum collection time points as Cohort A. Cohorts A \& B will be run nearly simultaneously as logistically feasible. Stage 2 (Cohorts C and D): After determining the PK parameters of single dose 800mg, the PK simulation model will be repeated, adjusting the model as needed based on findings from study Stage 1. Assuming there are no major discrepancies between Figure 2 (above) and the new PK simulations, the following regimens will be tested, beginning with Cohort C. Six subjects per dosing regimen, Cohorts C and D, will be admitted to the Johns Hopkins Bayview Medical Center, for a total of 12 subjects. The 800mg q12 hour x 2 regimen (Cohort C) will be tested first. For Cohort C, serum cefixime levels will be drawn at 12, 16, and 26 hours. If the q12 regimen is deemed safe and tolerable after review by the SMC, Cohort D will commence with the 800mg q8 hour x 3 regimen. Total serum cefixime levels will be drawn for Cohort D at 8, 16, 20 and 26 hours (see Section 7.2). All Stages, All Cohorts: All samples collected for PK analysis will be shipped to the University of Toledo, Dr. Jeffrey Blumer's HPLC lab for processing. Specimens will be analyzed by high performance liquid chromatography (HPLC) for total cefixime concentration levels. Targeted clinical evaluations will be used to monitor for subject reported side effects. Subjects will be asked about specific symptoms they may have experienced, including abdominal pain, nausea, vomiting, diarrhea, flatulence, headache, and rash, or any other symptoms. Additionally, subjects will be asked to maintain a Subject Diary (Appendix E) from Study Day 0 through Day 7 to record information about any symptoms experienced or medications taken. Study duration is approximately 47 weeks.
Concomitant use of benzodiazepines, including lorazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.

  


Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe lorazepam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of lorazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking lorazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response.

  


Advise both patients and caregivers about the risks of respiratory depression and sedation when lorazepam is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see PRECAUTIONS: Drug Interactions).
BACKGROUND: Visuospatial neglect is a common consequence of stroke and is characterized by impaired attention to contralesional space. Currently, the extent and time course of recovery from neglect are not clearly established. This systematic review and meta-analysis aimed to determine the recovery trajectory of poststroke neglect with standard treatment.
METHODS: PsycInfo, Embase, and MEDLINE were searched for articles reporting recovery rates of neglect after stroke. Time since stroke was categorized into early (0-3 months), mid (3-6 months), and late (>6 months) recovery phases. Random-effects models for pooled prevalence were generated for each phase, and potential sources of heterogeneity were explored with metaregressions. Methodological quality of each study was assessed using the Joanna Briggs Institute checklist, with low-quality studies excluded in sensitivity analyses.
RESULTS: The search captured 4130 articles including duplicates, and 111 full-text reviews were undertaken. A total of 27 studies reporting data from 839 stroke survivors with neglect were included for review. Meta-analyses indicated a recovery rate of 42% in the early phase, which increased to 53% in the mid-recovery phase. Additional recovery in the late phase was minimal, with an estimated 56% recovery rate. Heterogeneity of studies was high (I2>75%) in all 3 phases of recovery. Estimates were robust to sensitivity analyses. Metaregressions showed significantly greater recovery in studies that included patients with left-hemisphere lesions (β=0.275, P<0.05, I2=84%).
CONCLUSIONS: Most recovery from neglect occurs in the first 3 months, although additional gains can be expected up to 6 months poststroke. While a large proportion of patients recover from neglect, over 40% show persistent symptoms. Further research is needed on effective rehabilitation interventions, particularly focusing on patients most at risk of chronic visuospatial neglect.
REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42023388763.